文献速递泌尿生殖与妇科肿瘤放疗

立体定向盆腔放疗联合HDR近距离放疗推量治疗中高危前列腺癌(SPARE):疗效、毒性与生活质量

Stereotactic pelvic radiotherapy with HDR boost for dose escalation in intermediate and high-risk prostate cancer (SPARE): Efficacy, toxicity and quality of life.
PubMed 文献 · Radiother Oncol · 2021-06-03

中位随访61个月,5年生化失败率18.2%,4年PSA<0.4 ng/ml比例71%,急慢性≥2级泌尿和胃肠毒性可控,耐受性良好。

要点

  • MRI剂量绘画HDR-BT推量联合5次盆腔放疗和ADT耐受性良好。
  • 5年生化失败率18.2%,4年PSA<0.4 ng/ml比例71%。
  • 晚期≥2级泌尿毒性23%,胃肠毒性7%,仅1例晚期3级泌尿毒性。

核心结论

  • 含MRI剂量绘画HDR-BT推量、5次盆腔放疗和ADT的新方案耐受性良好。

主要发现

  • 5年生化失败率为18.2%,4年PSA<0.4 ng/ml比例为71%。
  • 急性2级和3级泌尿毒性分别为50%和7%,急性胃肠毒性2级为3%、无3级。
  • 晚期2级和3级泌尿毒性分别为23%和3%,晚期2级胃肠毒性为7%、无3级。
  • 生活质量最小临床重要变化比例:泌尿领域7.7%,肠道领域32.0%。
  • 1例患者死于前列腺癌。

关键数值与推荐

  • NCCN风险分组:3.2%有利中危、48.4%不利中危、48.4%高危。
  • HDR-BT剂量:前列腺15 Gy×1,MRI结节最多22.5 Gy。
  • 盆腔放疗:25 Gy分5次,每周一次。
  • ADT疗程6-18个月。
  • MRI结节中位D90为19.0 Gy,前列腺中位V100%为96.5%。

临床怎么用

  • 该方案可作为中高危前列腺癌患者BT推量的可选治疗策略,但需关注肠道生活质量下降。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The ASCO/CCO guidelines recommend brachytherapy (BT) boost for eligible intermediate- (IR) or high-risk (HR) prostate cancer (PCa) patients. We present efficacy, toxicity and quality-of-life (QoL) outcomes in patients treated on a prospective protocol of MRI dose-painted high-dose-rate BT boost (HDR-BT) followed by 5-fraction pelvic radiotherapy (RT) and 6-18 months of androgen deprivation therapy (ADT). METHODS: In this phase I/II study, IR or HR PCa patients received HDR-BT 15 Gy × 1 to prostate and up to 22.5 Gy to MRI nodule, followed by 25 Gy in 5, weekly fractions to pelvis. Toxicity was assessed using CTCAEv3.0, and QoL was captured using EPIC questionnaire. Biochemical failure (BF; nadir + 2.0), and proportion of patients with PSA < 0.4 ng/ml at 4-years (4yPSARR) were evaluated. A minimally clinically important change (MCIC) was recorded if QoL score decreased >0.5 standard deviation of baseline scores. RESULTS: Thirty-one patients (NCCN 3.2% favorable IR, 48.4% unfavorable IR and 48.4% HR) completed treatment with a median follow-up of 61 months. Median D90 to MR nodule was 19.0 Gy and median prostate V100% was 96.5%. The actuarial 5-year BF rate was 18.2%, and the 4yPSARR was 71%. One patient died of PCa. Acute grade 2 and 3 toxicities: GU: 50%, 7%, and GI: 3%, none, respectively. Late grade 2 and 3 toxicities were: GU: 23%, 3%, and GI: 7%, none, respectively. Proportion of patients with MCIC was 7.7% for urinary domain and 32.0% for bowel domain. CONCLUSIONS: This novel treatment protocol incorporating MRI dose-painted HDR-BT boost and 5-fraction pelvic RT with ADT is well tolerated.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Musunuru HB, Cheung P, Vesprini D, et al. Stereotactic pelvic radiotherapy with HDR boost for dose escalation in intermediate and high-risk prostate cancer (SPARE): Efficacy, toxicity and quality of life. Radiother Oncol. 2021. PMID: 34089752. doi:10.1016/j.radonc.2021.05.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。